Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study

Bitter, István; Treuer, Tamás; Dılbaz, Nesrin; Oyffe, Igor; Ciorabai, Eda M.; Gonzalez, Severiano L.; Ruschel, Sandra Inês; Salburg, J.; D’yachkova, Yulia

doi:10.3109/15622975.2010.505663

Cited by 29 publications

(34 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the percentage of subjects voluntarily taking medication increased significantly during the follow-up in the group treated with ODT, only. Thus, similar to the results the atypical neuroleptic form used had no significant effect on the patients' attitude towards the treatment [12,21]. It should also be noted that a positive attitude to treatment increased during the follow-up, regardless of the form of atypical neuroleptics used.…”

Section: Discussionsupporting

confidence: 69%

Obesity-related metabolic disturbances and quality of life in subjects diagnosed with schizophrenia treated with atypical neuroleptics

Ciura¹,

Chudek²,

Olszanecka-Glinianowicz³

2016

noms

View full text Add to dashboard Cite

Introduction: Weight gain and related metabolic disturbances are frequent side effects observed during treatment with atypical neuroleptics, most commonly with olanzapine and quetiapine. Weight gain may also deteriorate the quality of life and cause treatment discontinuation. However, the use of these neuroleptics in orodispensible tablet (ODT) form was related to lower frequency of weight gain. Therefore, the aim of this study was to evaluate the incidence of weight gain and metabolic disturbances in patients with schizophrenia treated with classical tablet (SOT) and orodispensible (ODT) formulations of olanzapine and quetiapine, and analyze the relationship between the occurrence of these side effects and quality of life and patient attitude to the treatment depending on the therapy used. Material and methods: A three-month questionnaire survey was performed by 400 psychiatrists from across Poland, during three consecutive outpatient visits. 4437 adult patients with schizophrenia treated with atypical neuroleptics for at least one month but not more than 12 months were enrolled. Results: Weight gain was significantly more common among patients treated with olanzapine than those treated with quetiapine (54.7% vs. 20%, p < 0.001 and 34.7% vs. 28.6%, p < 0.01, on visits 1 and 3, respectively), and was less frequently observed in patients treated with ODT formulations. The prevalence of hypertension and type 2 diabetes on the treatment did not change significantly. Treatment with olanzapine regardless of the form used was associated with a better quality of life and a more positive attitude of the patient towards the treatment. Conclusions: The risk of weight gain is greater during treatment with olanzapine than quetiapine. However, olanzapine use is associated with better quality of life and a more positive attitude of the patient towards the treatment. The use of neuroleptics in the ODT form may reduce the risk of weight gain but does not significantly affect the quality of life or the attitude of the patient towards the treatment.

show abstract

Section: Discussionsupporting

confidence: 69%

Obesity-related metabolic disturbances and quality of life in subjects diagnosed with schizophrenia treated with atypical neuroleptics

Ciura¹,

Chudek²,

Olszanecka-Glinianowicz³

2016

noms

View full text Add to dashboard Cite

show abstract

“…migraine, Parkinson's disease) [7][8][9] . Studies have shown distinct patient preference for ODTs over regular tablets in certain disease conditions [10][11][12] .…”

Section: Introductionmentioning

confidence: 99%

Formulation and development of orodispersible sustained release tablet of domperidone

Patil

Tiwari

Repka

et al. 2015

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

Abstract:Commercially available domperidone orodispersible tablets (ODT) are intended for immediate release of the drug but none of them have been formulated for sustained action. The aim of the present research work was to develop and evaluate orodispersible sustained release tablet (ODT-SR) of domperidone, which has the convenience of ODT and benefits of controlled release product combined in one. The technology comprised of developing sustained release microspheres (MS) of domperidone, followed by direct compression of MS along with suitable excipients to yield ODT-SR which rapidly disperses within 30 seconds and yet the dispersed MS maintain their integrity to have a sustained drug release. The particle size of the MS was optimized to be less than 200 μm to avoid the grittiness in the mouth. The DSC thermograms of MS showed the absence of drug-polymer interaction within the microparticles, while SEM confirmed their spherical shape and porous nature. Angle of repose, compressibility and Hausner's ratio of the blend for compression showed good flowability and high percent compressibility. The optimised ODT-SR showed disintegration time of 21 seconds and matrix controlled drug release for 9 h. Invivo pharmacokinetic studies in Wistar rats showed that the ODT-SR had a prolonged MRT of 11.16 h as compared 3.86 h of conventional tablet. The developed technology is easily scalable and holds potential for commercial exploitation.

show abstract

“…Of the fifteen clinical studies assessing the efficacy/effectiveness of ODO, two are RCTs: one is a double-blind parallel-arm trial assessing the safety of ODO compared with SOT as its primary objective27 and the other is an open-label crossover study assessing patient preference for ODO compared with SOT 28. Four observational cohort studies have also compared patients taking ODO and SOT 29–32.…”

Section: Clinical Studiesmentioning

confidence: 99%

“…Two RCTs27,28 and four prospective cohort studies29–32 compared the efficacy of ODO with SOT. Additionally, one relatively small (N = 38) retrospective open-label study utilized chronological sequential assignment of patients to ODO or SOT and used PANSS to compare the efficacy of these groups 35.…”

Section: Clinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties

Montgomery¹,

Treuer²,

Karagianis³

et al. 2012

PPA

View full text Add to dashboard Cite

Orally disintegrating olanzapine (ODO) is a rapid-dissolving formulation of olanzapine which disintegrates in saliva almost immediately, developed as a convenient and adherence-enhancing alternative to the standard olanzapine-coated tablet (SOT). Clinical studies, which form the basis of this review, have shown ODO and SOT to have similar efficacy and tolerability profiles. However, ODO appears to have a number of advantages over SOT in terms of adherence, patient preference, and reduction in nursing burden. Overall, the existing clinical data suggests that compared to SOT, ODO is not only well-suited for difficult-to-treat, agitated, and/or nonadherent patients but, due to its potential ability to improve adherence and greater patient preference, may also be an appropriate formulation for the majority of patients for which olanzapine is the antipsychotic of choice.

show abstract

Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study

Cited by 29 publications

References 37 publications

Obesity-related metabolic disturbances and quality of life in subjects diagnosed with schizophrenia treated with atypical neuroleptics

Obesity-related metabolic disturbances and quality of life in subjects diagnosed with schizophrenia treated with atypical neuroleptics

Formulation and development of orodispersible sustained release tablet of domperidone

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties

Contact Info

Product

Resources

About